0706 GMT - GSK's first-quarter results surpassed expectations, Intron Health analysts say in a note. Its specialty-medicines business outshined disappointing sales of its respiratory syncytial virus jab Arexvy, they say. The British drugmaker posted a 1% sales beat and a 7% EBIT beat, the analysts say. While guidance remains unchanged, the worsened foreign currency outlook presents a challenge, they add. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 30, 2025 03:06 ET (07:06 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.